Objective ErbB-2 is over expressed in relatively aggressive human breast tumours. When administered to patients together with chemotherapy, monoclonal antibodies to ErbB-2 (Trastuzumab(R)) effectively arrest tumours. Despite the great promise of this emerging modality, for an unknown reason many patients do not respond or develop intensivity. The study will address the underlying molecular mechanism with the hope of enhancing therapeutic efficacy. Co-over expression of topoisomerase IIbiased cross talk between ErbB-2 will be tested in clinical specimens, tumour-bearing animals and in cultured cells. Likewise, the potential synergistic effect of tyrosine kinase inhibitors and benzoquinoid ansamycins will be examined inpreclinical models. These studies are expected to better define patients eligible for therapy, reduce treatment costs and identify novel strategies of combination therapy. Fields of science medical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesbasic medicineimmunologyimmunotherapy Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-7. - Chronic and degenerative diseases, cancer, diabetes, cardivascular diseases and rare diseases Call for proposal Data not available Funding Scheme CSC - Cost-sharing contracts Coordinator UNIVERSITY OF TAMPERE Address 6,lenkkeilijänkatu 6 33014 Tampere Finland See on map EU contribution € 0,00 Participants (3) Sort alphabetically Sort by EU Contribution Expand all Collapse all MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. Germany EU contribution € 0,00 Address 11,am fassberg 11 37077 Göttingen - nikolausberg See on map UNIVERSITY OF DEBRECEN Hungary EU contribution € 0,00 Address Nagyerdei krt.98 4012 Debrecen See on map WEIZMANN INSTITUTE OF SCIENCE Israel EU contribution € 0,00 Address 2 herzel street 76100 Rehovot See on map
